RxDoctor Payments Data

Donald Johnson, DPM

Primary Podiatric Medicine · Ormond Beach, FLNPI 1386637700

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.4% of the total across 44 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 15 manufacturers reported payments, led by Smith+Nephew at 30.5% of the total.

$1,727in general payments, 2019–2025

Across 44 payments — averaging $39.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Smith+Nephew$527
  • Organogenesis Inc.$310
  • Linvatec Corporation$155
  • Integra Lifesciences Corporation$138
  • Acera Surgical, Inc.$122
  • Octapharma USA, Inc.$114
  • plus $362 from 9 others

What the payments were for

  • Consulting fees$1147%
  • Food & beverage$1,61393%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,727 in reported general payments places this provider in the 65th percentile of 68 primary podiatric medicine providers in Florida.

See all primary podiatric medicine providers in Florida

Medicare billing

Part B allowed, 2024
$313,335
Medicare patients
687
Services billed
2,670

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gabapentin438$3,077
Betamethasone Dipropionate41$2,159
Diclofenac Sodium79$2,029
Methylprednisolone302$1,948
Gentamicin Sulfate20$1,107
Pregabalin34$656
Meloxicam218$506
Clindamycin Hcl73$459
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip13$430
Cephalexin31$332
Ciprofloxacin Hcl51$324
Terbinafine Hcl20$321
Celecoxib23$315
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen38$160
Ketoconazole13$129

Paid to pharmacies, not to this prescriber.

Other primary podiatric medicine in Ormond Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →